Assessing the Effect of High Performance Inulin Supplementation via KLF5 mRNA Expression in Adults with Type 2 Diabetes: A Randomized Placebo Controlled Clinical Trail

Advanced Pharmaceutical Bulletin
Q1
Mar 2018
Citations:27
Influential Citations:1
Interventional (Human) Studies
90
S2 IconPDF Icon

Enhanced Details

Methods
Randomized, double-blind, placebo-controlled clinical trial in adults with type 2 diabetes; 46 participants aged 30–50 years were randomly allocated to HP inulin (n=23) or placebo (n=23) for 6 weeks, using randomized block procedure with stratification by gender and age.
Intervention
HP inulin powder, 10 g per day, divided into two 5 g doses taken before breakfast and before dinner, for 6 weeks.
Results
HP inulin 10 g/day significantly lowered fasting plasma glucose vs placebo (P<0.001). KLF5 mRNA expression in PBMCs decreased (fold change 0.61 ± 0.11; P=0.001). Plasma miR-375 increased (fold change 3.75 ± 0.70; P=0.004). No significant between-group differences for HbA1c, fasting insulin, lipids, weight, or BMI; waist and hip circumference decreased within the HP inulin group. Interpretation: HP inulin may support glycemic control in type 2 diabetes by modulating KLF5 and miR-375; further larger and longer studies are needed to confirm and clarify mechanisms.
Limitations
Small sample size; short duration (6 weeks); limited biomarker scope (no inflammatory markers, short-chain fatty acids, or other glucose-regulation genes).

Abstract

Purpose: The worldwide prevalence of metabolic disorders such as diabetes is increasing rapidly. Currently, the complications of diabetes are the major health concern. The aim of this study was to investigate the effect of high performance (HP) inuli...